Abstract
Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].
| Original language | English |
|---|---|
| Pages (from-to) | 176-181 |
| Number of pages | 6 |
| Journal | Seminars in Fetal and Neonatal Medicine |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1 Jun 2019 |
Fingerprint
Cite this
}
Optimizing antenatal corticosteroid therapy. / Kemp, Matthew W.; Schmidt, Augusto F.; Jobe, Alan H.
In: Seminars in Fetal and Neonatal Medicine, Vol. 24, No. 3, 01.06.2019, p. 176-181.Research output: Contribution to journal › Article
TY - JOUR
T1 - Optimizing antenatal corticosteroid therapy
AU - Kemp, Matthew W.
AU - Schmidt, Augusto F.
AU - Jobe, Alan H.
PY - 2019/6/1
Y1 - 2019/6/1
N2 - Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].
AB - Treatment with antenatal corticosteroids (ACS) is standard of care for women at risk of preterm birth between 24 and 34 weeks’ gestation. ACS are increasingly used for other indications, including threated or indicated late preterm birth, elective cesarean, and in at-risk pregnancies for periviable gestations. However, the various drugs and doses being used worldwide have not been rigorously evaluated to optimize clinical responses and to minimize potential risks. Translational research in animal models indicate that a constant, low concentration fetal exposure to ACS is sufficient for lung maturation, resulting in lower fetal exposures. Clinical trials to develop dosing strategies with inexpensive and widely available drugs could promote greater use in low resource environments. “Even the best proven interventions must be evaluated continually through research for their safety, effectiveness, efficacy, accessibility and quality,” Declaration of Helsinki [1].
KW - Betamethasone
KW - Dexamethasone
KW - Maturation
KW - Pharmacology
KW - Prematurity
UR - http://www.scopus.com/inward/record.url?scp=85065624770&partnerID=8YFLogxK
U2 - 10.1016/j.siny.2019.05.003
DO - 10.1016/j.siny.2019.05.003
M3 - Article
VL - 24
SP - 176
EP - 181
JO - Seminars in Fetal & Neonatal Medicine
JF - Seminars in Fetal & Neonatal Medicine
SN - 1084-2756
IS - 3
ER -